阿布昔替尼治疗成人中重度特应性皮炎JADE COMPARE随机3期研究的患者报告结局
JADE COMPARE是一项多中心3期随机双盲安慰剂对照试验,成人中重度特应性皮炎患者按2:2:2:1随机接受16周口服阿布昔替尼200 mg或100 mg每日一次、度普利尤单抗300 mg皮下注射每2周一次或安慰剂,均联合背景外用治疗。第16周时两种剂量阿布昔替尼在多项患者报告结局上均较安慰剂显著改善,200 mg阿布昔替尼的效应数值上大于度普利尤单抗。
要点
- 第16周POEM评分<3的比例:阿布昔替尼200 mg为21.3%、100 mg为11.7%,度普利尤单抗为12.4%,安慰剂为4.8%。
- 第16周NTIS严重度较基线改善≥4分的比例:阿布昔替尼200 mg为64.3%、100 mg为52.4%,度普利尤单抗为54.0%,安慰剂为34.4%。
- 第16周DLQI较基线改善≥4分的比例:阿布昔替尼200 mg为85.0%、100 mg为74.4%,度普利尤单抗为83.4%,安慰剂为59.7%。
核心结论
- 两种剂量阿布昔替尼较安慰剂均使患者报告结局显著改善,200 mg阿布昔替尼较度普利尤单抗的效应在数值上更大。
研究设计与样本
- JADE COMPARE为多中心3期随机双盲安慰剂对照试验,成人中重度特应性皮炎患者按2:2:2:1随机分组,接受16周口服阿布昔替尼200 mg或100 mg每日一次、度普利尤单抗300 mg皮下注射每2周一次或安慰剂,均联合背景外用治疗。
主要发现
- 第16周POEM评分<3的比例:阿布昔替尼200 mg为21.3%、100 mg为11.7%,度普利尤单抗为12.4%,安慰剂为4.8%(阿布昔替尼200 mg vs 安慰剂P<0.0001,100 mg vs 安慰剂P=0.04)。
- 第16周NTIS严重度较基线改善≥4分的比例:阿布昔替尼200 mg为64.3%、100 mg为52.4%,度普利尤单抗为54.0%,安慰剂为34.4%(阿布昔替尼200 mg vs 安慰剂P<0.0001,100 mg vs 安慰剂P=0.007)。
- 第16周DLQI较基线改善≥4分的比例:阿布昔替尼200 mg为85.0%、100 mg为74.4%,度普利尤单抗为83.4%,安慰剂为59.7%(阿布昔替尼200 mg vs 安慰剂P<0.0001,100 mg vs 安慰剂P=0.005)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. OBJECTIVES: We examined clinically meaningful improvements in selected patient-reported outcomes (PROs). METHODS: JADE COMPARE was a multicentre, phase 3 randomized, double-blind, placebo-controlled trial. Adults with moderate-to-severe AD were randomized 2:2:2:1 to receive 16 weeks of oral abrocitinib 200 or 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo, with background topical therapy. PROs included Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Night Time Itch Scale (NTIS), Pruritus and Symptoms Assessment for Atopic Dermatitis, Patient Global Assessment, SCORing Atopic Dermatitis, and Hospital Anxiety and Depression Scale. RESULTS: At week 16, the proportion of patients achieving POEM scores <3 was 21.3% and 11.7% for 200 and 100 mg abrocitinib, 12.4% for dupilumab, and 4.8% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.04). Proportion achieving ≥4-point improvement from baseline in NTIS severity was 64.3% and 52.4% for 200 and 100 mg abrocitinib, 54.0% for dupilumab, and 34.4% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.007). Proportion achieving ≥4-point improvement from baseline in DLQI was 85.0% and 74.4% for 200 and 100 mg abrocitinib, 83.4% for dupilumab, and 59.7% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.005). CONCLUSION: Significant improvements in PROs were demonstrated with both abrocitinib doses vs. placebo, and abrocitinib 200 mg provided numerically greater effects compared with dupilumab in patients with moderate-to-severe AD.
引用
- Thyssen JP, Yosipovitch G, Paul C, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2021. PMID: 34779063. doi:10.1111/jdv.17813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。